Head to head
Ipamorelin vs Selank
A comparison decided mostly by evidence: Selank has been studied in people to a degree the other has not.
Verdict
Selank rests on firmer evidence
What you are actually choosing between
These sit in different classes. Ipamorelin is a growth hormone secretagogue; Selank is a nootropic. They get compared because of where they overlap, not because they are interchangeable.
The overlap is recovery and sleep. On this site's goal weighting — an editorial priority score, not a measure of effect size — Ipamorelin rates 4/5 for recovery and sleep and Selank rates 4/5. Outside that overlap they diverge: Ipamorelin also carries weight for injury repair and muscle growth, Selank for focus and cognition.
The evidence
This is the part that decides most of it. Selank has approval from a regulator somewhere, though not a current FDA or EMA label — a registered Russian medicine; the trials are small and Russian-language. Ipamorelin has some human data, but it is small, old, or uncontrolled — small early-phase work only; development was discontinued. That gap is the headline, and it is a statement about the literature rather than a promise about you: a compound with trial data can still do nothing for your case, and one without it is unproven rather than disproven.
How they differ in practice
Ipamorelin is a subcutaneous injection; Selank is a nasal spray and a subcutaneous injection. That is the difference most people actually feel: Ipamorelin means reconstituting a vial and injecting; Selank does not require either. If needles are the deciding factor, this line settles it before any of the rest matters.
Ipamorelin has a characterized half-life of 2 h; Selank does not have one published here at all. That asymmetry is worth more than it looks — it usually tracks how much formal pharmacology has been done on a compound.
Committed time differs: Ipamorelin runs 12 weeks, Selank runs 2 weeks.
Risk and difficulty
The contraindication lists are not the same: Ipamorelin flags active malignancy, which Selank does not. If any of those describe you they remove a compound from consideration outright, regardless of everything above.
Ipamorelin is rated beginner here and Selank intermediate. That rating is about how much can go wrong in handling, dosing and monitoring, not about how well either works.
Source notes
What the evidence actually says
Verbatim, so you can check the verdict above against what it was built from.
Ipamorelin
Selective ghrelin receptor (GHS-R1a) agonist that triggers a growth hormone pulse with little effect on cortisol or prolactin, which is the main reason it is chosen over hexarelin or GHRP-6. Published human work is limited to small early-phase and post-operative ileus studies; development was discontinued and it is NOT an approved medicine anywhere. Everything sold to consumers is research-chemical grade, so the community 100-300 mcg per dose range comes from practice rather than from a label.
Selank
A synthetic heptapeptide analogue of the immune peptide tuftsin, again with a Pro-Gly-Pro tail added for stability. Its character is anxiolytic rather than stimulant, which is why it is usually paired with, not substituted for, Semax. Like Semax it is a Russian-registered intranasal medicine (commonly a 0.15% solution) and is NOT approved in the US or EU; the human evidence is small Russian trials in generalised anxiety disorder and adjustment disorder, some comparing it against benzodiazepines such as phenazepam, and it has not been independently replicated in Western trials. Route matters: it is an intranasal drug, not an injectable. Russian clinical dosing runs to roughly 1800-2700 mcg per day divided across two or three administrations; the per-dose range here reflects the more conservative doses typical of non-clinical use rather than the full trial daily total. Plasma half-life is minutes, so no hourly figure is listed. Courses are conventionally short (10-14 days) rather than continuous.
Side by side
The numbers
| Attribute | Ipamorelin | Selank |
|---|---|---|
| Class | GH secretagogue | Nootropic |
| Routes | Subcutaneous | Intranasal, Subcutaneous |
| Dose range | 100 mcg–300 mcg (typical 200 mcg) | 150 mcg–900 mcg (typical 300 mcg) |
| Frequency | Once daily | Twice daily |
| Half-life | 2 h | Not characterized |
| Cycle length | 12 weeks | 2 weeks |
| Experience | Beginner | Intermediate |
| Evidence | Limited human data | Approved elsewhere |
| Contraindications |
|
|
| Side effects |
|
|
Turn a typical dose into a mark on the syringe: IpamorelinSelank
Goals
Where they overlap, and where they do not
| Goal | Ipamorelin | Selank |
|---|---|---|
| recovery and sleep | Ipamorelin: 4/5 | Selank: 4/5 |
| focus and cognitionone only | Ipamorelin: — | Selank: 3/5 |
| injury repairone only | Ipamorelin: 3/5 | Selank: — |
| muscle growthone only | Ipamorelin: 3/5 | Selank: — |
| fat lossone only | Ipamorelin: 2/5 | Selank: — |
| immune supportone only | Ipamorelin: — | Selank: 2/5 |
| longevityone only | Ipamorelin: 2/5 | Selank: — |
| neuroprotectionone only | Ipamorelin: — | Selank: 2/5 |
They overlap on 1 goal and diverge on 7. Weights are this site’s editorial priority score out of 5 — how central a goal is to why people use a compound. They are not effect sizes and two 5s do not mean two equal results.
Next
Go deeper
Related
Other comparisons with these two
Educational information only, not medical advice. Talk to a licensed clinician before starting, changing, or stopping anything.